P3.01-064 Detection of EGFR Mutations in Circulating Tumor DNA Using Plasma Samples: Clinical Validation of Cobas EGFR Mutation Test V2

Abstract

Detection of EGFR mutations in circulating tumor DNA using plasma samples is non-invasive and safety method. Cobas EGFR mutation test v2 with tumor tissue has been approved for detection of EGFR mutations to offer EGFR-TKI therapy in Japan. Recently, cobas test v2 using plasma samples at disease progression after prior EGFR-TKI therapy was approved for detection of T790M mutation. However, diagnostic accuracy of this test using plasma samples has not yet known in clinical practice.